SOLODYN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOLODYN (SOLODYN).
Solodyn (minocycline hydrochloride) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain.
| Metabolism | Minocycline is metabolized in the liver via oxidative pathways, producing multiple metabolites including 9-hydroxyminocycline and 8-hydroxyminocycline. Enzymes involved include CYP450 isozymes, though specific isozymes are not well characterized. |
| Excretion | Primarily renal (40-70% unchanged) via glomerular filtration; significant biliary/fecal (20-30%) as unchanged drug and metabolites. Enterohepatic recirculation occurs. |
| Half-life | Terminal elimination half-life: 11-22 hours (mean ~16 hours). Clinically, steady-state reached in 3-4 days; half-life prolonged in renal impairment. |
| Protein binding | 75-80% bound primarily to serum albumin. |
| Volume of Distribution | 0.7-1.5 L/kg; extensive tissue distribution including bone, liver, and tumor tissues. |
| Bioavailability | Oral: 90-100% (immediate-release); reduced to 75-85% with food (but food decreases nausea). Extended-release (Solodyn) has 100% relative bioavailability compared to immediate-release. |
| Onset of Action | Oral: 1-2 hours for detectable serum levels; clinical effects (anti-inflammatory) may take 2-4 weeks for rosacea. |
| Duration of Action | Therapeutic effects persist for 24 hours after oral dosing, supporting once-daily regimen; anti-inflammatory effects may continue for weeks after discontinuation. |
| Molecular Weight | 493.56 |
1 mg/kg orally once daily as extended-release tablets; not to exceed 100 mg/day. Alternatively, 1 mg/kg orally once daily as immediate-release tablets; not to exceed 100 mg/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | For severe renal impairment (CrCl <30 mL/min), administer 50% of usual dose or consider alternative therapy. |
| Liver impairment | No specific dose adjustment recommended in mild to moderate hepatic impairment; use caution in severe hepatic impairment (Child-Pugh class C). |
| Pediatric use | For children 12 years and older: 1 mg/kg orally once daily as extended-release tablets, not to exceed 100 mg/day. For children under 12 years: not FDA approved for this age group. |
| Geriatric use | In elderly patients, no specific dose adjustment recommended; monitor for renal function and potential increased adverse effects (e.g., photosensitivity, gastrointestinal disturbances). |
| 1st trimester | Avoid due to teratogenicity: tetracyclines can cause fetal harm including retardation of skeletal development and reversible inhibition of bone growth. |
| 2nd trimester | Avoid due to risk of permanent discoloration of teeth (yellow-gray-brown) and enamel hypoplasia; use only if no alternatives. |
| 3rd trimester | Avoid due to same risks as second trimester; potential for fetal hepatotoxicity and pancreatitis. |
Clinical note
Comprehensive clinical and safety monograph for SOLODYN (SOLODYN).
| Placental transfer | Tetracyclines readily cross the placenta; levels in fetal circulation are approximately 60-70% of maternal serum levels. |
| Breastfeeding | Tetracyclines are excreted in breast milk in low amounts, but due to potential for dental staining and bone growth inhibition in infants, avoid or use alternative if possible. American Academy of Pediatrics considers tetracyclines compatible with breastfeeding for short-term use, but caution is advised. |
■ FDA Black Box Warning
None FDA boxed warning specific to Solodyn. However, tetracycline-class antibiotics have a class warning regarding photosensitivity and should be used with caution in patients with hepatic or renal impairment.
| Serious Effects |
Hypersensitivity to tetracyclinesPregnancyChildren under 8 years of age (due to tooth discoloration)Severe hepatic impairmentSystemic lupus erythematosus
| Precautions | Photosensitivity: exaggerated sunburn reaction; avoid sunlight or tanning beds., Hepatotoxicity: rare but serious; discontinue if signs of liver injury occur., Pseudotumor cerebri (intracranial hypertension): headache, blurred vision, papilledema., Drug-induced lupus and autoimmune syndromes., Superinfection: use of antibiotics may result in overgrowth of nonsusceptible organisms, including fungi., Use with caution in patients with renal impairment as minocycline is excreted renally., Contains FD&C Yellow No. 6 (tartrazine) which may cause allergic reactions in susceptible individuals. |
| Food/Dietary | Absorption is decreased by food, especially meals high in fat. Take on an empty stomach. Avoid concurrent administration with dairy products, calcium-fortified foods, and supplements containing calcium, magnesium, aluminum, iron, or zinc. |
Loading safety data…
| Lactation Rating | L4 (Limited Data - Possibly Hazardous) |
| Teratogenic Risk | Category D. Tetracyclines cause fetal harm (retarded skeletal development, dental discoloration, enamel hypoplasia). Avoid in second and third trimesters. Use only if no alternative. |
| Fetal Monitoring | Monitor maternal liver function, renal function, and complete blood count. Assess fetal growth and development via ultrasound if exposure occurs in second/third trimester. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies show no impairment at therapeutic doses. |
| Clinical Pearls | SOLODYN (minocycline hydrochloride extended-release) is a tetracycline antibiotic. Clinical pearls: Use for moderate to severe inflammatory acne vulgaris. Food significantly decreases absorption; take on empty stomach. Avoid use in children <8 years due to permanent tooth discoloration and bone growth inhibition. Monitor for autoimmune syndromes (e.g., drug-induced lupus, hepatitis). Photosensitivity reactions possible; warn about sun/UV exposure. Dosage adjustment needed in renal impairment. Do not use during pregnancy (category D). |
| Patient Advice | Take SOLODYN on an empty stomach, at least 1 hour before or 2 hours after meals. · Avoid dairy products, antacids, iron, calcium, magnesium, and zinc supplements within 2 hours of taking this medication. · Drink plenty of fluids to reduce risk of esophageal irritation. · Do not use if pregnant or planning to become pregnant; use effective contraception. · Use sunscreen and protective clothing; avoid prolonged sun exposure as this drug increases sun sensitivity. · Report symptoms of severe headache, vision changes, joint pain, or yellowing of skin/eyes immediately. · Complete full course of therapy even if symptoms improve. · Store at room temperature (59-86°F or 15-30°C) away from heat and moisture. |